Efficacy of CDK4/6 Inhibitor in Treatment of Metastatic Breast Cancer and Colon Cancer
Janet Raycheva,
Teodora Karanikolova,
Rossitza Krusteva,
Margarita Taushanova-Hadjieva
Issue:
Volume 5, Issue 1, March 2020
Pages:
1-4
Received:
21 October 2019
Accepted:
30 December 2019
Published:
8 January 2020
Abstract: A 52-years old woman was diagnosed with an invasive left-sided ductal breast cancer, G3 – staged as T2N0M0; Estrogen (ER) 3+, Progesterone (PR) +, Human epidermal growth factor receptor 2 (HER 2) negative, Ki67-11%. She underwent a radical mastectomy, followed by adjuvant chemotherapy and hormone treatment with Tamoxifen. A year later she was diagnosed with a colorectal cancer-low grade, G1; histological results of adenocarcinoma - T3N1M1 with liver metastases. After a biopsy, which revealed that the metastases are coming from the breast (ER+/HER 2 (-) Breast cancer - (GATA (3+)), she was restaged as T3N1M0. The patient started treatment with Ribociclib 600mg/d + Letrozole 2,5mg/d with a partial response of the disease after three months of treatment. Due to G3 neutropenia, the dose was adjusted to 400 mg/d. Last restaging: October 2019 – complete response and a good quality of life. This case approves that the CDK (cyclin-dependent kinase) 4/6 inhibitors are able to manage visceral metastases and to provide long-term survival without worsening the quality of life. Her disease is successfully managed with CDK4/6 inhibitor together with hormonal therapy, which proves the effect of the CDK 4/6 inhibitors in treatment not only to breast cancer. Six months after there are no signs of relapse of the colon cancer. Despite the stage of the second cancer – T3N1M0, the patient did not undergo adjuvant treatment for the colon cancer.
Abstract: A 52-years old woman was diagnosed with an invasive left-sided ductal breast cancer, G3 – staged as T2N0M0; Estrogen (ER) 3+, Progesterone (PR) +, Human epidermal growth factor receptor 2 (HER 2) negative, Ki67-11%. She underwent a radical mastectomy, followed by adjuvant chemotherapy and hormone treatment with Tamoxifen. A year later she was diagn...
Show More
Therapeutic Attitude in the Malignification of Pilonidal Cyst: Radical Treatment Associating Intraoperative Radiotherapy
Natalia Noblejas Quiles,
Virginia Morillo Macías,
Araceli Mayol Oltra,
Fernando Ibáñez Palacín,
Jorge Molina Saera,
Rafael Lozoya Albalar,
Enrique Boldó Roda,
Stephane Antonio De Francia Cachon,
María Eloísa Villaverde Domenech,
Isabel Busquier Hernández,
Carlos Ferrer Albiach
Issue:
Volume 5, Issue 1, March 2020
Pages:
5-9
Received:
7 December 2019
Accepted:
26 December 2019
Published:
8 January 2020
Abstract: Malignant degeneration on pilonidal cyst is an infrequent entity: less than 70 cases have been described in the literature. Predominantly in males around 50-60. Very slow evolution until its malignancy. Predilection for the sacrococcygeal area and epidermoid histology. Infrequent distant dissemination despite the important local extension of the primary tumor. Similar morphological and histological characteristics to anal carcinomas, using schemes of treatment based on radiotherapy and chemotherapy with radical intention according to locoregional and distance extension, associating subsequent surgery depending on the response. We describe a case of this pathology and its therapeutic management based on the literature review available. We present the case of a 70-year-old man with a pilonidal cyst malignancy in the sacrococcygeal region. Locally advanced and unresectable disease at diagnosis with skin, muscle, lymphatic and bone involvement. Pathological confirmation diagnosis established after thick needle biopsy, with a well-differentiated squamous cell carcinoma. It was decided to administer chemotherapy and radiotherapy treatment and, depending on the response evaluated by nuclear magnetic resonance, excision and/or intraoperative radiotherapy in the area of microscopic risk disease. In a second time, reconstruction using glute flaps. Early diagnosis and treatment are essential to improve the unfortunate prognosis. Surgery with curative intention is the standard of care according to locoregional extension in association with radiotherapy and chemotherapy if adverse factors or unresectable disease. In order to enhance local control, dose has been scaled allowing, besides, to minimize the acute toxicity derived from the treatment.
Abstract: Malignant degeneration on pilonidal cyst is an infrequent entity: less than 70 cases have been described in the literature. Predominantly in males around 50-60. Very slow evolution until its malignancy. Predilection for the sacrococcygeal area and epidermoid histology. Infrequent distant dissemination despite the important local extension of the pr...
Show More
The Relationship Between Sarcopenia and Cancer Chemotherapys
Fufeng Zhang,
Shasha Yang,
Qiong Chen,
Xiaoqin Lu
Issue:
Volume 5, Issue 1, March 2020
Pages:
10-15
Received:
19 January 2020
Accepted:
30 March 2020
Published:
14 April 2020
Abstract: As an independent disease, characterized by progressive and generalized loss of skeletal muscle mass, quality and strength, Sarcopenia has become a research hotspot in recent years, and its position in cancer patients has been increasingly valued by clinicians. Clarifying the relationship between Sarcopenia and chemotherapeutics in the treatment of cancer patients will help to formulate interventions for Sarcopenia to improve the quality of life and prolong survival period of cancer patients. In order to understand the relationship between Sarcopenia and cancer chemotherapy, we review from the following aspects. How is Sarcopenia diagnosed in cancer patients? How to evaluate Sarcopenia in cancer patients? What is the incidence of Sarcopenia in cancer patients? What is the relationship between the changes in body composition and the dose of chemotherapy in cancer patients? Whether there is a relationship between Sarcopenia and chemotherapy-related toxicity in cancer patients? Its role in leading to chemotherapy toxicity and its effect on the prognosis and survival in cancer patients. Whether chemotherapeutic drugs have an effect on the development of Sarcopenia in cancer patients, or whether certain types of chemotherapy drugs will affect Sarcopenia? Finally, the review also aims to describe interventions for Sarcopenia and their impact on the outcome of treatment for cancer patients.
Abstract: As an independent disease, characterized by progressive and generalized loss of skeletal muscle mass, quality and strength, Sarcopenia has become a research hotspot in recent years, and its position in cancer patients has been increasingly valued by clinicians. Clarifying the relationship between Sarcopenia and chemotherapeutics in the treatment of...
Show More
